Announcements
- Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
- Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
- Life Science Cares Launches in Switzerland
- Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
- Molecular Partners Publishes Invitation to Annual General Meeting 2024
- Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
- Molecular Partners Announces Dismissal of Class Action Lawsuit
- Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
- Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
More ▼
Key statistics
On Friday, Molecular Partners AG (0QXX:LSE) closed at 3.36, 10.53% above the 52 week low of 3.04 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 3.38 |
Average volume | 506.00 |
---|---|
Shares outstanding | 36.68m |
Free float | 33.31m |
P/E (TTM) | -- |
Market cap | 124.17m CHF |
EPS (TTM) | -1.78 CHF |
Data delayed at least 20 minutes, as of May 24 2024 16:19 BST.
More ▼